Please use this identifier to cite or link to this item:
標題: 犬惡性末梢神經鞘瘤PLOD2表現與組織病理學特徵的相關
Association between PLOD2 expression and histopathological characteristics in canine malignant peripheral nerve sheath tumors
作者: 劉佑安
You-An Liu
關鍵字: 膠原基質
extracellular matrix (ECM)
malignant peripheral nerve sheath tumor (MPNST)
tumor microenvironment (TME)
引用: Anghileri, M., Miceli, R., Fiore, M., Mariani, L., Ferrari, A., Mussi, C., Lozza, L., Collini, P., Olmi, P., Casali, P.G., 2006. Malignant peripheral nerve sheath tumors. Cancer 107, 1065-1074. Avallone, G., Helmbold, P., Caniatti, M., Stefanello, D., Nayak, R., Roccabianca, P., 2007. The spectrum of canine cutaneous perivascular wall tumors: morphologic, phenotypic and clinical characterization. Veterinary Pathology 44, 607-620. Bacon, N.J., Dernell, W.S., Ehrhart, N., Powers, B.E., Withrow, S.J., 2007. Evaluation of primary re-excision after recent inadequate resection of soft tissue sarcomas in dogs: 41 cases (1999–2004). Journal of the American Veterinary Medical Association 230, 548-554. BAKER‐GABBy, M., Hunt, G., France, M., 2003. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Australian Veterinary Journal 81, 732-738. Boos, G.S., Bassuino, D.M., Wurster, F., Castro, N.B., Watanabe, T.T., Silva, G.S., Sonne, L., Driemeier, D., 2015. Retrospective canine skin peripheral nerve sheath tumors data with emphasis on histologic, immunohistochemical and prognostic factors. Pesquisa Veterinária Brasileira 35, 965-974. Bostock, D., Dye, M., 1980. Prognosis after surgical excision of canine fibrous connective tissue sarcomas. Veterinary Pathology 17, 581-588. Brønden, L.B., Eriksen, T., Kristensen, A.T., 2010. Mast cell tumours and other skin neoplasia in Danish dogs-data from the Danish Veterinary Cancer Registry. Acta Veterinaria Scandinavica 52, 6. Bray, J.P., Polton, G.A., McSporran, K.D., Bridges, J., Whitbread, T.M., 2014a. Canine soft tissue sarcoma managed in first opinion practice: outcome in 350 cases. Veterinary Surgery 43, 774-782. Bray, J.P., Worley, D.R., Henderson, R.A., Boston, S.E., Mathews, K.G., Romanelli, G., Bacon, N.J., Liptak, J.M., Scase, T.J., 2014b. Hemipelvectomy: outcome in 84 dogs and 16 cats. A veterinary society of surgical oncology retrospective study. Veterinary Surgery 43, 27-37. Brehm, D.M., Vite, C.H., Steinberg, H.S., Haviland, J., Van Winkle, T., 1995. A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. Journal of the American Animal Hospital Association 31, 349-359. Brosius, S.N., Turk, A.N., Byer, S.J., Longo, J.F., Kappes, J.C., Roth, K.A., Carroll, S.L., 2014. Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades. Journal of Neuropathology & Experimental Neurology 73, 1078-1090. Carroll, S.L., Ratner, N., 2008. How does the Schwann cell lineage form tumors in NF1? Glia 56, 1590-1605. Chase, D., Bray, J., Ide, A., Polton, G., 2009. Outcome following removal of canine spindle cell tumours in first opinion practice: 104 cases. Journal of Small Animal Practice 50, 568-574. Chen, Y., Guo, H., Terajima, M., Banerjee, P., Liu, X., Yu, J., Momin, A.A., Katayama, H., Hanash, S.M., Burns, A.R., 2016. Lysyl hydroxylase 2 is secreted by tumor cells and can modify collagen in the extracellular space. Journal of Biological Chemistry 291, 25799-25808. Chijiwa, K., Uchida, K., Tateyama, S., 2004. Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue sarcomas. Veterinary Pathology 41, 307-318. Coindre, J.M., 2006. Grading of soft tissue sarcomas: review and update. Archives of pathology & laboratory medicine 130, 1448-1453. Conklin, M.W., Eickhoff, J.C., Riching, K.M., Pehlke, C.A., Eliceiri, K.W., Provenzano, P.P., Friedl, A., Keely, P.J., 2011. Aligned collagen is a prognostic signature for survival in human breast carcinoma. The American journal of pathology 178, 1221-1232. Demetriou, J., Brearley, M., Constantino‐Casas, F., Addington, C., Dobson, J., 2012. Intentional marginal excision of canine limb soft tissue sarcomas followed by radiotherapy. Journal of Small Animal Practice 53, 174-181. Dennis, M., McSporran, K., Bacon, N., Schulman, F., Foster, R., Powers, B., 2011. Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Veterinary Pathology 48, 73-84. Dong, S., Nutt, C.L., Betensky, R.A., Stemmer-Rachamimov, A.O., Denko, N.C., Ligon, K.L., Rowitch, D.H., Louis, D.N., 2005. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. Journal of Neuropathology & Experimental Neurology 64, 948-955. Du, H., Pang, M., Hou, X., Yuan, S., Sun, L., 2017. PLOD2 in cancer research. Biomedicine & Pharmacotherapy 90, 670-676. Ducatman, B.S., Scheithauer, B.W., Piepgras, D.G., Reiman, H.M., Ilstrup, D.M., 1986. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57, 2006-2021. Ehrhart, N., 2005. Soft-tissue sarcomas in dogs: a review. Journal of the American Animal Hospital Association 41, 241-246. Eisinger-Mathason, T.K., Zhang, M., Qiu, Q., Skuli, N., Nakazawa, M.S., Karakasheva, T., Mucaj, V., Shay, J.E., Stangenberg, L., Sadri, N., 2013. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discovery 3, 1190-1205. Elmslie, R., Glawe, P., Dow, S., 2008. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of veterinary internal medicine 22, 1373-1379. Engellau, J., Samuelsson, V., Anderson, H., Bjerkehagen, B., Rissler, P., Sundby-Hall, K., Rydholm, A., 2007. Identification of low-risk tumours in histological high-grade soft tissue sarcomas. European Journal of Cancer 43, 1927-1934. Ettinger, S.N., Scase, T.J., Oberthaler, K.T., Craft, D.M., McKnight, J.A., Leibman, N.F., Charney, S.C., Bergman, P.J., 2006. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996—2002). Journal of the American Veterinary Medical Association 228, 1053-1062. Fukushima, S., Endo, M., Matsumoto, Y., Fukushi, J.-i., Matsunobu, T., Kawaguchi, K.-i., Setsu, N., IIda, K., Yokoyama, N., Nakagawa, M., 2017. Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. PloS One 12, 19. Gilkes, D.M., Bajpai, S., Wong, C.C., Chaturvedi, P., Hubbi, M.E., Wirtz, D., Semenza, G.L., 2013. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Molecular Cancer Research 11, 456-466. Gjaltema, R.A., de Rond, S., Rots, M.G., Bank, R.A., 2015. Procollagen lysyl hydroxylase 2 expression is regulated by an alternative downstream transforming growth factor β-1 activation mechanism. Journal of Biological Chemistry 290, 28465-28476. Hendrick, M., Mahaffey, E., Moore, F., Vos, J., Walder, E., Histological classification of mesenchymal tumors of skin and soft tissues of domestic animals. 1998 vol II, Series ed. Washington DC. Hohenhaus, A.E., Kelsey, J.L., Haddad, J., Barber, L., Palmisano, M., Farrelly, J., Soucy, A., 2016. Canine cutaneous and subcutaneous soft tissue sarcoma: an evidence-based review of case management. Journal of the American Animal Hospital Association 52, 77-89. Huijbers, I.J., Iravani, M., Popov, S., Robertson, D., Al-Sarraj, S., Jones, C., Isacke, C.M., 2010. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PloS One 5, e9808. Işeri, Ö.D., Kars, M.D., Arpaci, F., Gündüz, U., 2010. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemotherapy and Pharmacology 65, 447-455. Julius, M.L., Lisa, J.F., 2013. Soft tissue sarcomas, In: Withrow and MacEwen's Small Animal Clinical Oncology. W.B. Saunders, Saint Louis, pp. 356-380. Kindblom, L.G., Angervall, L., 1975. Histochemical characterization of mucosubstances in bone and soft tissue tumors. Cancer 36, 985-994. Kirpensteijn, J., Kik, M., Rutteman, G., Teske, E., 2002. Prognostic significance of a new histologic grading system for canine osteosarcoma. Veterinary Pathology 39, 240-246. Kroep, J., Ouali, M., Gelderblom, H., Le Cesne, A., Dekker, T., Van Glabbeke, M., Hogendoorn, P., Hohenberger, P., 2010. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Annals of Oncology 22, 207-214. Kuntz, C., Dernell, W., Powers, B., Devitt, C., Straw, R., Withrow, S., 1997. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). Journal of the American Veterinary Medical Association 211, 1147-1151. Kurozumi, A., Kato, M., Goto, Y., Matsushita, R., Nishikawa, R., Okato, A., Fukumoto, I., Ichikawa, T., Seki, N., 2016. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. International Journal of Oncology 48, 1837-1846. Kwon, S.-Y., Chae, S.W., Wilczynski, S.P., Arain, A., Carpenter, P.M., 2012. Laminin 332 expression in breast carcinoma. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry 20, 159. Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., Fong, S.F., Csiszar, K., Giaccia, A., Weninger, W., 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906. Li, H., Zhang, X., Fishbein, L., Kweh, F., Campbell-Thompson, M., Perrin, G.Q., Muir, D., Wallace, M., 2010. Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells. Cancer biology & therapy 10, 758-764. Lintz, F., Moreau, A., Odri, G.-A., Waast, D., Maillard, O., Gouin, F., 2012. Critical study of resection margins in adult soft-tissue sarcoma surgery. Orthopaedics & Traumatology: Surgery & Research 98, S9-S18. Louis, D.N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica 131, 803-820. Lu, P., Weaver, V.M., Werb, Z., 2012. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196, 395-406. McKnight, J.A., Mauldin, G.N., McEntee, M.C., Meleo, K.A., Patnaik, A.K., 2000. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. Journal of the American Veterinary Medical Association 217, 205-210. McSporran, K., 2009. Histologic grade predicts recurrence for marginally excised canine subcutaneous soft tissue sarcomas. Veterinary Pathology 46, 928-933. Miyamoto, K., Seki, N., Matsushita, R., Yonemori, M., Yoshino, H., Nakagawa, M., Enokida, H., 2016. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. British Journal of Cancer 115, 354. Monteiro, B., Boston, S., Monteith, G., 2011. Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: a retrospective study in 100 dogs. The Canadian Veterinary Journal 52, 1209-1214. Noda, T., Yamamoto, H., Takemasa, I., Yamada, D., Uemura, M., Wada, H., Kobayashi, S., Marubashi, S., Eguchi, H., Tanemura, M., 2012. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver International 32, 110-118. Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Calin, G.A., Santarpia, L., 2016. Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental & Clinical Cancer Research 35, 19. Palmieri, C., Avallone, G., Cimini, M., Roccabianca, P., Stefanello, D., Salda, L.D., 2013. Use of electron microscopy to classify canine perivascular wall tumors. Veterinary Pathology 50, 226-233. Pankova, D., Chen, Y., Terajima, M., Schliekelman, M.J., Baird, B.N., Fahrenholtz, M., Sun, L., Gill, B.J., Vadakkan, T.J., Kim, M.P., 2016. Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Molecular Cancer Research 14, 287-295. Patarroyo, M., Tryggvason, K., Virtanen, I., 2002. Laminin isoforms in tumor invasion, angiogenesis and metastasis, In: Seminars in cancer biology, pp. 197-207. Perry, J., Culp, W., Dailey, D., Eickhoff, J., Kamstock, D., Thamm, D., 2014. Diagnostic accuracy of pre‐treatment biopsy for grading soft tissue sarcomas in dogs. Veterinary and Comparative Oncology 12, 106-113. Pervaiz, N., Colterjohn, N., Farrokhyar, F., Tozer, R., Figueredo, A., Ghert, M., 2008. A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma. Cancer 113, 573-581. Postorino, N., 1988. Prognostic variables for canine hemangiopericytoma: 50 cases (1974-1984). Journal of the American Animal Hospital Association 24, 501-509. Quail, D.F., Joyce, J.A., 2013. Microenvironmental regulation of tumor progression and metastasis. Nature medicine 19, 1423. Rajkumar, T., Sabitha, K., Vijayalakshmi, N., Shirley, S., Bose, M.V., Gopal, G., Selvaluxmy, G., 2011. Identification and validation of genes involved in cervical tumourigenesis. BMC cancer 11, 80. Remmele, W., Stegner, H., 1987. A proposal for the standardization of the immunoreactive score (Irs) for the immunohistochemical demonstration of estrogen-receptors (Er-Ica) in breast-cancer. Pathologe 8, 138-140. Ricard-Blum, S., 2011. The collagen family. Cold Spring Harbor perspectives in biology 3, a004978. Sampo, M., Tarkkanen, M., Tukiainen, E., Popov, P., Gustafson, P., Lundin, M., Böhling, T., Blomqvist, C., Lundin, J., 2012. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. British Journal of Cancer 106, 1076. Scaravilli, F., 1989. Diagnostic Manual of Tumours of the Central Nervous System. Journal of Neurology, Neurosurgery, and Psychiatry 52, 815. Selting, K.A., Powers, B.E., Thompson, L.J., Mittleman, E., Tyler, J.W., Lafferty, M.H., Withrow, S.J., 2005. Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996–2004). Journal of the American Veterinary Medical Association 227, 1442-1448. Sian, C.S., Ryan, S.F., 1981. The ultrastructure of neurilemoma with emphasis on Antoni B tissue. Human Pathology 12, 145-160. Smith, T.M., Lee, M.K., Szabo, C.I., Jerome, N., McEuen, M., Taylor, M., Hood, L., King, M.-C., 1996. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome research 6, 1029-1049. Spencer, V.A., Xu, R., Bissell, M.J., 2007. Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress. Advances in Cancer Research 97, 275-294. Stefanello, D., Avallone, G., Ferrari, R., Roccabianca, P., Boracchi, P., 2011. Canine cutaneous perivascular wall tumors at first presentation: clinical behavior and prognostic factors in 55 cases. Journal of veterinary internal medicine 25, 1398-1405. Stefanello, D., Morello, E., Roccabianca, P., Iussich, S., Nassuato, C., Martano, M., Squassino, C., Avallone, G., Romussi, S., Buracco, P., 2008. Marginal Excision of Low‐Grade Spindle Cell Sarcoma of Canine Extremities: 35 Dogs (1996–2006). Veterinary Surgery 37, 461-465. Subramanian, S., West, R.B., Marinelli, R.J., Nielsen, T.O., Rubin, B.P., Goldblum, J.R., Patel, R.M., Zhu, S., Montgomery, K., Ng, T.L., 2005. The gene expression profile of extraskeletal myxoid chondrosarcoma. The Journal of pathology 206, 433-444. Suzuki, S., Uchida, K., Nakayama, H., 2014. The effects of tumor location on diagnostic criteria for canine malignant peripheral nerve sheath tumors (MPNSTs) and the markers for distinction between canine MPNSTs and canine perivascular wall tumors. Veterinary Pathology 51, 722-736. Takagi, H., Azuma, K., Osaki, T., Itoh, N., Nakazumi, S., Taura, Y., Okamoto, Y., 2014. High temperature hyperthermia treatment for canines exhibiting superficial tumors: A report of three cases. Oncology letters 8, 2055-2058. Willems, S., Schrage, Y., Baelde, J., Briaire‐de Bruijn, I., Mohseny, A., Sciot, R., Bovee, J., Hogendoorn, P., 2008. Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition. Histopathology 52, 465-474. Willems, S.M., Wiweger, M., van Roggen, J.F.G., Hogendoorn, P.C., 2010. Running GAGs: myxoid matrix in tumor pathology revisited. Virchows Archiv 456, 181-192. Wippold, F., Lubner, M., Perrin, R., Lämmle, M., Perry, A., 2007. Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns. American Journal of Neuroradiology 28, 1633-1638. Xiong, G.F., Xu, R., 2016. Function of cancer cell-derived extracellular matrix in tumor progression. Journal of Cancer Metastasis and Treatment 2, 358. Xu, F., Zhang, J., Hu, G., Liu, L., Liang, W., 2017a. Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell International 17, 54. Xu, Y., Zhang, L., Wei, Y., Zhang, X., Xu, R., Han, M., Huang, B., Chen, A., Li, W., Zhang, Q., 2017b. Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion. Oncotarget 8, 23401-23413. Yoshizawa, A., Motoi, N., Riely, G.J., Sima, C.S., Gerald, W.L., Kris, M.G., Park, B.J., Rusch, V.W., Travis, W.D., 2011. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology 24, 653.
摘要: Procollagenlysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2)為穩定膠原纖維結構的重要酵素。腫瘤微環境對於許多腫瘤的進展和侵犯行為有關,而PLOD2則藉由調節細胞外基質的組成影響腫瘤微環境。惡性末梢神經鞘瘤是犬最常見的軟組織肉瘤,雖然相較於其它軟組織肉瘤而言具有較良性的生物行為,仍有少部分惡性末梢神經鞘瘤發生局部復發或遠端轉移。本實驗目的為評估PLOD2在惡性末梢神經鞘瘤的表現與其在組織病理學特徵和預後之關聯性。本研究包括取自105隻犬的共110個惡性末梢神經鞘瘤,藉由西方墨點法確認PLOD2抗體與犬的組織之特異結合後,再以免疫組織化學染色分析PLOD2抗體在腫瘤組織的表現;腫瘤細胞外基質則藉由Masson's trichrome與Alcian blue pH2.5特殊染色分別突顯膠原與黏液基質的表現。結果發現共78.2% (86/110)的腫瘤樣本具有PLOD2表現。單變因分析顯示PLOD2的表現與臨床分期、腫瘤內的膠原基質含量、腫瘤分化程度、壞死灶多寡和組織分級顯著相關(P<0.05);多變因分析則發現PLOD2與腫瘤的侵犯生長(P=0.046)與較多膠原基質含量(P=0.011)成正相關。在存活分析方面,PLOD2的表現僅於單變因分析結果發現為影響整體存活時間的負面預後因子(P=0.028),其它不良的預後因子包括有絲分裂數目高(P=0.048)、遠端轉移(P=0.004)、腫瘤局部復發(P=0.004)和未接受手術治療(P=0.001)皆在多變因結果具統計顯著性。總括而言,犬惡性末梢神經鞘瘤的腫瘤細胞之PLOD2表現與腫瘤內的膠原基質含量和侵犯的生長模式具正相關性,但無法作為單一獨立的預後因子。
Procollagenlysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) is an enzyme that modify the extracellular matrix (ECM) in tumor microenviroment (TME) through stabilizing the cross-links of collagen. This alteration in ECM was thought to play a role in tumor progression and aggressive behaviors in many tumors. Malignant peripheral nerve sheath tumor (MPNST) is the most common soft tissue sarcoma (STS) in dogs. Since the universal benign biological behavior compare with other STSs, some MPNST still appear with aggressive manners such as local recurrence and distant metastasis. The aim of this study was to evaluate the association of PLOD2 expression, histopathological characteristics and prognostic factors in canine MPNSTs. The total of 110 MPNSTs from 105 dogs were enrolled. The specific binding of PLOD2 antibody was identified by Western blotting. While PLOD2 was analyzed immunohistochemically, Masson's Trichrome and Alcian blue pH 2.5 were used to highlight collagenous and mucinous stroma, respectively. The immunoreactivity of PLOD2 was detected in 78.2% (86/110) of tumors. In univariate analysis, the immunoreactivity of PLOD2 was significantly (P<0.05) correlated with clinical stage, collagenous stroma in tumor parenchyma, degree of differentiation, amount of necrosis, and histological grade. In the multivariate model, presence of invasive growth pattern of tumor cells (P=0.046) and greater amount of collagenous stroma (P=0.011) were significantly associated with PLOD2 expression. The stronger immunoreactivity of PLOD2 was correlated to shorter overall survival time in univariate analysis (P=0.028) but not in multivariate model. Other poor prognostic factors in multivariate model include high mitotic figures (P=0.048), presence with distant metastasis (P=0.004) and tumor local recurrence (P=0.004), and absence of surgical management (P=0.001). In conclusion, this study revealed the positive correlation of PLOD2 immunoreactivity with the amount of collagenous stroma and invasive growth pattern of tumor cells as well; however, PLOD2 might not be used as a sole prognostic factor for canine MPNSTs.
文章公開時間: 2018-08-15
Appears in Collections:獸醫學系所



Show full item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.